Katarina LeBlanc - Publications, H-index & Citations

Katarina LeBlanc

Karolinska Institutet

19H指数

58论文数

2.6K被引数

收录论文 16

发表时间

Remembering Arnold Caplan

CYTOTHERAPY

IF3.2

2024-07-01

PREAI

LeBlanc, Katarina; Pittenger, Mark; Martin, Ivan; Galipeau, Jacque; Horwitz, Edwin M.; Sowmya, Viswanathan

Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition

CYTOTHERAPY

IF3.2

2021-05-01

OAAI

Galipeau, Jacques; Krampera, Mauro; Leblanc, Katarina; Nolta, Jan A.; Phinney, Donald G.; Shi, Yufang; Tarte, Karin; Viswanathan, Sowmya; Martin, Ivan

Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential

CYTOTHERAPY

IF3.2

2020-11-01

OAAI

Khoury, Maroun; Rocco, Patricia R. M.; Phinney, Donald G.; Krampera, Mauro; Martin, Ivan; Viswanathan, Sowmya; Nolta, Jan A.; LeBlanc, Katarina; Galipeau, Jacques; Weiss, Daniel J.

Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells-first phase I/II human clinical study: commentary to response

STEM CELL RESEARCH & THERAPY

IF7.3

2020-06-16

OAAI

Hertegard, Stellan; LeBlanc, Katarina

Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells-first phase I/II human clinical study

STEM CELL RESEARCH & THERAPY

IF7.3

2020-03-20

OAAI

Hertegard, Stellan; Nagubothu, Srinivasa Rau; Malmstrom, Emma; LeBlan, Katarina

Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature 间充质干细胞与基质细胞: 国际细胞与基因治疗学会 (ISCT®) 间充质基质细胞委员会关于命名法的立场声明

CYTOTHERAPY

IF3.2

2019-10-01

530

PREAI

Viswanathan, S.; Shi, Y.; Galipeau, J.; Krampera, M.; Leblanc, K.; Martin, I; Nolta, J.; Phinney, D. G.; Sensebe, L.

ORAL PROGENITOR CELL REGULATION OF FIRST LINE DEFENSE AND ITS DYSREGULATION IN CHRONIC GRAFT VERSUS HOST DISEASE

CYTOTHERAPY

IF3.2

2018-05-01

PREAI

Davies, L.; Board-Davies, E.; Tour, G.; Shamlou, B.; Sloan, A.; Stephens, P.; LeBlanc, K. L.

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

HAEMATOLOGICA

IF7.9

2016-11-24

OAAI

Scharenberg, Christian; Giai, Valentina; Pellagatti, Andrea; Saft, Leonie; Dimitriou, Marios; Jansson, Monika; Jadersten, Martin; Grandien, Alf; Douagi, Iyadh; Neuberg, Donna S.; LeBlanc, Katarina; Boultwood, Jacqueline; Karimi, Mohsen; Jacobsen, Sten Eirik W.; Woll, Petter S.; Hellstrom-Lindberg, Eva

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

CYTOTHERAPY

IF3.2

2016-02-01

424

OAAI

Galipeau, Jacques; Krampera, Mauro; Barrett, John; Dazzi, Francesco; Deans, Robert J.; Debruijn, Joost; Dominici, Massimo; Fibbe, Willem E.; Gee, Adrian P.; Gimble, Jeffery M.; Hematti, Peiman; Koh, Mickey B. C.; Leblanc, Katarina; Martin, Ivan; McNiece, Ian K.; Mendicino, Michael; Oh, Steve; Ortiz, Luis; Phinney, Donald G.; Planat, Valerie; Shi, Yufang; Stroncek, David F.; Viswanathan, Sowmya; Weiss, Daniel J.; Sensebe, Luc

MSCs: science and trials

NATURE MEDICINE

IF50

2013-07-08